Sagar Lonial, MD, and James O. Armitage, MD, on Relapsed/Refractory Multiple Myeloma: The ELOQUENT-2 Trial and a Phase II Study of Daratumumab
2015 ASCO Annual Meeting
James O. Armitage, MD, of the University of Nebraska Medical Center, and Sagar Lonial, MD, of Emory University School of Medicine, discuss results from two important studies that tested lenalidomide/dexamethasone with or without elotuzumab and daratumumab monotherapy (Abstracts 8508 and LBA8512).
Related Videos
David E. Gerber, MD, and James L. Mulshine, MD
James L. Mulshine, MD, of Rush University Medical Center, and David E. Gerber, MD, of The University of Texas Southwestern Medical Center, discuss the ALCHEMIST trial, an NCI initiative to address the role of molecular testing and targeted therapies for earlier-stage lung disease (Abstract TPS7583).
Andrew James Martin, PhD, and Anthony J. Olszanski, RPh, MD
Andrew James Martin, PhD, of NHMRC Clinical Trials Centre, University of Sydney, and Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, discuss a form of vitamin B3 that reduced the incidence of new nonmelanoma skin cancers in high-risk patients (Abstract 9000).
Patrick Schöffski, MD
Patrick Schöffski, MD, of the University Hospital Leuven, discusses a phase III study in which he and his colleagues found, for the first time in soft-tissue sarcomas, a significant overall survival benefit of a single agent compared to a standard treatment (Abstract LBA10502).
Howard M. Sandler, MD, and Christopher Sweeney, MBBS
Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, and Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discuss the improvement of overall survival with the use of adjuvant chemotherapy following androgen suppression and radiotherapy (Abstract LBA5002).
Ruben A. Mesa, MD, and James O. Armitage, MD
James O. Armitage, MD, of The University of Nebraska Medical Center, and Ruben A. Mesa, MD, of the Mayo Clinic, discuss pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).